CiteULike
Facebook
Mendeley
Twitter
This article is- freely available
- re-usable
Cancers 2011, 3(2), 2554-2596; doi:10.3390/cancers3022554
Review
State of the Art in Tumor Antigen and Biomarker Discovery
INSERM U624, 163 avenue de Luminy, 13288 Marseille Cedex 09, France
* Author to whom correspondence should be addressed.
Received: 6 April 2011; in revised form: 24 May 2011 / Accepted: 27 May 2011 / Published: 9 June 2011
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
Download PDF Full-Text [417 KB, uploaded 9 June 2011 09:58 CEST]
Abstract: Our knowledge of tumor immunology has resulted in multiple approaches for the treatment of cancer. However, a gap between research of new tumors markers and development of immunotherapy has been established and very few markers exist that can be used for treatment. The challenge is now to discover new targets for active and passive immunotherapy. This review aims at describing recent advances in biomarkers and tumor antigen discovery in terms of antigen nature and localization, and is highlighting the most recent approaches used for their discovery including “omics” technology.
Keywords: tumor antigen; biomarkers; immunotherapy; cancer; proteomics
Article Statistics
Click here to load and display the download statistics.Cite This Article
MDPI and ACS Style
Even-Desrumeaux, K.; Baty, D.; Chames, P. State of the Art in Tumor Antigen and Biomarker Discovery. Cancers 2011, 3, 2554-2596.
AMA StyleEven-Desrumeaux K, Baty D, Chames P. State of the Art in Tumor Antigen and Biomarker Discovery. Cancers. 2011; 3(2):2554-2596.
Chicago/Turabian StyleEven-Desrumeaux, Klervi; Baty, Daniel; Chames, Patrick. 2011. "State of the Art in Tumor Antigen and Biomarker Discovery." Cancers 3, no. 2: 2554-2596.